US Stock MarketDetailed Quotes

SMTI Sanara MedTech

Watchlist
  • 27.790
  • -1.610-5.48%
Close Apr 4 16:00 ET
  • 27.790
  • 0.0000.00%
Post 16:05 ET
247.38MMarket Cap-24.38P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

Comments

    $Sanara MedTech (SMTI.US)$
    Biomimetic Innovations Ltd, an affiliate of PBC Biomed, Announces an Exclusive License and Distribution Agreement and Minority Investment with Sanara MedTech Inc.
    Friday, 24th January at 7:00 am
    SHANNON, Ireland, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Irish medical device company Biomimetic Innovations Limited, an affiliate of PBC Biomed, today announced the execution of an exclusive license and distribution agreement with Sanara MedTech Inc ("Sanara") (NASDAQ: SMTI). I...
    $Sanara MedTech (SMTI.US)$
    Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd
    Tuesday, 21st January at 4:10 pm
    OsStic® and related technologies represent differentiated solutions that address an estimated 100,000+ procedures in the U.S. annually(1); arrangement leverages Sanara's existing call points and commercial infrastructure, and complements Sanara's existing surgical portfolio
    FORT WORTH, TX, Jan. 21,...
    $Sanara MedTech (SMTI.US)$
    Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024
    Tuesday, 21st January at 4:05 pm
    Fourth Quarter Net Revenue Expected to Increase 45% to 48% Year-Over-Year; Full Year Net Revenue Expected to Increase 32% to 33% Year-Over-Year
    FORT WORTH, TX, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ: SMTI), a medic...
    $Sanara MedTech (SMTI.US)$
    NEWS
    Sanara MedTech Inc. Announces $55 Million Debt Facility
    Sanara MedTech's balance sheet is strained due to liabilities and lack of profitability. Its use of debt is risky, given its negative EBIT and free cash flow. However, its top-line growth is viewed positively.
Read more

Market Insights

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.

Discussing

FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More